Biotech Values

[DewDiligence]

RETA IPOs 6.33M* shares @$11.00:

http://finance.yahoo.com/news/reata-pharmaceuticals-inc-announces-pricing-031907581.html

Reata Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing product candidates that modulate the activity of key regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with a variety of serious or life-threatening diseases.

Reata used to be known as the Bardoxolone company (#msg-54747777, #msg-80651463 [oops]).

*Assuming exercise of underwriter’s option.